-
2024-513912-89-00
10
2018-12-13
Primary Or Secondary (Post-PV MF or Post-ET-MF) Myelofibrosis (MF) Wit
-
2023-509354-58-00
5
2017-07-14
Mantle Cell Lymphoma
-
2023-510434-83-00
6
2016-10-17
Chronic Myeloid Leukemia (CML) in Chronic Phase (CP)
-
2022-500630-29-00
5
2016-05-06
Subjects with High Risk Invasive Urothelial Carcinoma
-
2023-507889-89-00
5
2016-02-19
Respiratory tract infection
-
2024-511640-11-00
5
2014-05-15
Follicular lymphoma
-
2024-515152-20-00
4
2023-03-02
Stage III and high-risk stage II resected colon cancer patients.
-
2022-502367-37-00
7
2024-11-29
Recurrent glioblastoma multiforme (GBM)
-
2023-508663-70-00
4
2024-06-18
Bronchiectasis
-
2023-507667-19-00
3
2024-06-06
Polymyalgia rheumatica (PMR)
-
2023-503693-20-01
5
2024-04-10
Severe eosinophilic asthma
-
2022-501421-20-00
5
2024-04-09
Gout with hyperuricemia
-
2023-504678-39-00
4
2024-03-13
Heart Failure
-
2023-505487-11-00
5
2023-12-21
Actinic Keratosis on the Face or Scalp
-
2023-503315-15-00
4
2023-12-20
Thrombolysis of symptomatic proximal vein thrombosis
-
2022-501895-25-00
5
2023-09-13
Polymyalgia Rheumatica
-
2022-502828-42-00
4
2023-09-01
Idiopathic Pulmonary Fibrosis
-
2022-502196-31-00
10
2023-08-21
Advanced or Recurrent Endometrial Cancer
-
2022-501794-39-00
5
2023-06-28
Uveitic Macular Edema
-
2022-501351-82-00
4
2023-05-23
Dermatomyositis, Polymyositis
-
2022-501793-19-00
5
2023-04-21
Uveitic Macular Edema
-
2024-514714-12-00
10
2022-11-11
Metastatic Pancreatic Ductal Adenocarcinoma
-
2023-507430-25-00
1
2022-10-03
Relapsed and/or refractory B-cell Non-Hodgkin lymphoma (R/R B-NHL) and
-
2024-513992-42-00
10
2022-09-13
venous thromboembolism (VTE) in patients with gastrointestinal/genitou